FundedIQ
Biotechnology

Regenosine

a privately held corporation specialising in the creation and promotion of world-class regenerative treatments for osteoarthritis Our patented platform technology taps into the purinergic system's capacity for healing, which is essential for preserving the homeostasis of cartilage. Our flagship product, which targets the rapidly expanding joint preservation industry, is a patented formulation for regenerating cartilage in joints with established osteoarthritis. Our objective is to provide patients with a disease-modifying therapy with uncompromised efficacy in comparison to currently available technology. We will considerably enhance clinical results and patient quality of life by creating this disease-modifying medication, and we will lower the overall costs of regenerative medicine-related health care delivery.

regenosine.com New Jersey, Trinidad and Tobago 11-50 employees
Total raised
$30k
Rounds
1
Latest
Series Unknown
Feb 2023

a privately held corporation specialising in the creation and promotion of world-class regenerative treatments for osteoarthritis Our patented platform technology taps into the purinergic system's capacity for healing, which is essential for preserving the homeostasis of cartilage. Our flagship product, which targets the rapidly expanding joint preservation industry, is a patented formulation for regenerating cartilage in joints with established osteoarthritis. Our objective is to provide patients with a disease-modifying therapy with uncompromised efficacy in comparison to currently available technology. We will considerably enhance clinical results and patient quality of life by creating this disease-modifying medication, and we will lower the overall costs of regenerative medicine-related health care delivery.

Regenosine has raised $30k across 1 round. Its most recent round was a Series Unknown of $30k in Feb 2023. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Feb 16, 2023
Series Unknown
$30k

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Regenosine is featured in

Similar companies

LifeMine Therapeutics

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.

Series E $188M
Metaphore Biotechnologies

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

Series Unknown
BRAINBox Solutions

BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.

Series Unknown
CND Life Sciences

CND Life Sciences is committed to supporting patients with neurodegenerative diseases, offering the Syn-One Test® as a first-of-its-kind tool to detect and measure misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This test helps confirm synucleinopathies like Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company operates a CLIA-certified and CAP-accredited lab in Scottsdale, AZ, providing a convenient and accurate alternative for diagnosis through skin biopsies. Additionally, CND collaborates with biopharmaceutical companies to advance research in the field.

Private Equity
Protoga

Protoga is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.

Series A $14.8M
Dash Bio

Dash Bio is a cutting-edge platform that employs AI, robotics, and fully integrated software to revolutionize the process of drug development and bring new medications to market.

Series A $30.0M
Yuantian Bio

Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications.

Series A $14.8M
Genomenon

Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making. It revolutionizes the way genetic diagnoses and discoveries are made. The company’s suite of diagnostic and discovery tools enable physicians, pharma, and researchers to quickly and accurately identify disease-causing variants from genomic-sequencing datasets. It was founded in 2014 and is headquartered in Ann Arbor, Michigan.

Series Unknown $6.0M
Adjuvia Therapeutics

Adjuvia Therapeutics is a clinical-stage biopharmaceutical company.

Seed $8.0M
CoreMap

CoreMap exists to improve patient outcomes by delivering advanced diagnostic technology to electrophysiologists and patients.

Series C $37.0M
Sonavex

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

Series Unknown $3.1M
NewLine

NewLine researches phage feed additives to prevent livestock infections.

Series A $14.8M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.